论文部分内容阅读
癌胚抗原(CEA)是临床上诊断结直肠癌最重要标志物,尤其对根治术后病人监测非常有用。CA19-9化学结构与CEA不同,是一种糖成份,作为鉴定Lewis血型的一种物质。有关血清中CA19-9在结直肠癌病人的术后或化疗后的研究甚少,本文研究目的在于对晚期结直肠癌病人血清中CEA和CA19-9的系列分析来预测化疗疗效、肿瘤进展的时间及病人的预后。作者收集了1984年10月至1990年7月间的85例晚期结直肠癌病人,所有病例均已发现转移或未能切除的活检证实结直肠癌。采用EMF化疗方案,即阿霉素(20mg/m~2)、氨甲喋呤(150mg/m~2)、5-FU(600mg/m~2),一周3次用药,间歇2～3周,治疗直至病情恶化。疗效评价通过每四周进行一次
Carcinoembryonic antigen (CEA) is the most important marker for the clinical diagnosis of colorectal cancer, and it is especially useful for monitoring patients after radical resection. The chemical structure of CA19-9, unlike CEA, is a sugar component that is used as a substance to identify Lewis blood type. There is very little research about serum CA19-9 in patients with colorectal cancer after surgery or chemotherapy. The purpose of this study is to analyze the serum levels of CEA and CA19-9 in patients with advanced colorectal cancer to predict the efficacy of chemotherapy and tumor progression. Time and patient’s prognosis. The authors collected 85 patients with advanced colorectal cancer between October 1984 and July 1990. All cases had metastatic or unresected biopsy confirmed colorectal cancer. The EMF chemotherapy regimens were doxorubicin (20 mg/m~2), methotrexate (150 mg/m~2), and 5-FU (600 mg/m~2), administered 3 times a week, intermittent for 2 to 3 weeks, until treatment The condition deteriorated. Efficacy evaluation is done once every four weeks